Insmed Incorporated (NASDAQ:INSM) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP reduced its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 16.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 326,500 shares of the biopharmaceutical company's stock after selling 66,200 shares during the period. Two Sigma Advisers LP owned approximately 0.18% of Insmed worth $22,542,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of INSM. Park Avenue Securities LLC raised its stake in shares of Insmed by 42.1% in the fourth quarter. Park Avenue Securities LLC now owns 7,955 shares of the biopharmaceutical company's stock valued at $549,000 after acquiring an additional 2,358 shares in the last quarter. Atomi Financial Group Inc. increased its holdings in Insmed by 6.6% in the fourth quarter. Atomi Financial Group Inc. now owns 24,774 shares of the biopharmaceutical company's stock valued at $1,710,000 after buying an additional 1,526 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in Insmed by 5.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company's stock valued at $244,000 after buying an additional 183 shares during the last quarter. Avior Wealth Management LLC purchased a new position in Insmed in the fourth quarter valued at $157,000. Finally, Blue Trust Inc. increased its holdings in Insmed by 25.7% in the fourth quarter. Blue Trust Inc. now owns 2,462 shares of the biopharmaceutical company's stock valued at $180,000 after buying an additional 503 shares during the last quarter.

Insmed Stock Performance

INSM traded up $1.37 during trading on Friday, reaching $67.53. The company's stock had a trading volume of 1,545,805 shares, compared to its average volume of 2,334,404. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91. The company's fifty day moving average price is $70.69 and its 200-day moving average price is $73.05. The company has a market capitalization of $12.30 billion, a price-to-earnings ratio of -12.08 and a beta of 0.84. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $92.82 million during the quarter, compared to analysts' expectations of $91.63 million. During the same period in the prior year, the firm posted ($1.06) EPS. Insmed's revenue for the quarter was up 22.9% compared to the same quarter last year. On average, equities analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Insmed

In other news, insider Orlov S. Nicole Schaeffer sold 4,999 shares of Insmed stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $67.81, for a total transaction of $338,982.19. Following the completion of the sale, the insider now directly owns 115,879 shares in the company, valued at approximately $7,857,754.99. This trade represents a 4.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Michael Alexander Smith sold 409 shares of Insmed stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $65.61, for a total value of $26,834.49. Following the transaction, the insider now owns 91,794 shares of the company's stock, valued at $6,022,604.34. This represents a 0.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 153,098 shares of company stock valued at $10,724,192. 3.00% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

INSM has been the topic of several recent analyst reports. Truist Financial increased their target price on Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a report on Friday, February 21st. UBS Group dropped their target price on Insmed from $110.00 to $109.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Royal Bank of Canada reiterated an "outperform" rating and set a $100.00 target price on shares of Insmed in a research report on Wednesday, March 19th. Wells Fargo & Company lifted their target price on Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 19th. Finally, Bank of America lifted their target price on Insmed from $92.00 to $96.00 and gave the stock a "buy" rating in a research report on Thursday, March 20th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $94.63.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.